Paper Details

  1. Home
  2. Paper Details

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.

Author: FrickM H, KaumaH, KesäniemiY A, MajahalmeS, NieminenM S, PasternackA, SyvänneM, TaskinenM R, VirtanenV

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Gemfibrozil therapy retarded the progression of coronary atherosclerosis and the formation of bypass-graft lesions in post-coronary bypass men with low HDL cholesterol.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Studies have shown that treatment of hyperlipidemia, especially lowering of plasma LDL levels, retards the progression of coronary atherosclerosis and prevents clinical cardiovascular events. No such studies have focused on subjects with low levels of HDL cholesterol. METHODS AND RESULT...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1161/01.cir.96.7.2137

データ提供：米国国立医学図書館（NLM）

Gemfibrozil for the Prevention of Atherosclerosis Progression After Coronary Bypass Surgery

Coronary heart disease, a leading cause of morbidity and mortality, is a major focus of medical research. This study investigates the potential of gemfibrozil, a lipid-lowering medication, in preventing the progression of coronary and vein-graft atherosclerosis in men with low levels of HDL cholesterol following coronary bypass surgery.

The study, a randomized controlled trial involving 395 men with low HDL cholesterol and LDL cholesterol, compared the effects of gemfibrozil (1200 mg/d) to placebo. The primary outcome was the change in coronary dimensions assessed by computer-assisted analysis of coronary angiograms performed at baseline and after an average of 32 months of therapy.

Gemfibrozil's Potential to Slow Atherosclerosis Progression

The results showed that gemfibrozil therapy significantly retarded the progression of coronary atherosclerosis and the formation of bypass-graft lesions in men with low HDL cholesterol. This suggests that gemfibrozil may have a beneficial effect on preventing the progression of atherosclerosis in this specific patient population.

A Promising Strategy for Atherosclerosis Prevention

This study provides encouraging evidence for the potential of gemfibrozil in slowing the progression of atherosclerosis in men with low HDL cholesterol. The findings highlight the importance of individualizing treatment strategies based on specific lipid profiles, aiming to optimize cardiovascular health.

Dr.Camel's Conclusion

The desert of cardiovascular disease is vast and unforgiving. This study reveals the potential of gemfibrozil to help navigate this landscape by slowing the progression of atherosclerosis. The findings suggest that individualized treatment approaches, tailored to specific lipid profiles, are crucial for maintaining cardiovascular health and preventing the development of coronary heart disease.

Date :
  1. Date Completed 1997-10-31
  2. Date Revised 2019-06-23
Further Info :

Pubmed ID

9337181

DOI: Digital Object Identifier

10.1161/01.cir.96.7.2137

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.